Online inquiry

IVTScrip™ mRNA-Anti-HA, MHAA4549A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11652MR)

This product GTTS-WQ11652MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets HA gene. The antibody can be applied in Influenza B infection research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq YP_308669.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3654620
UniProt ID Q9Q0U6
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-HA, MHAA4549A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ11652MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14549MR IVTScrip™ mRNA-Anti-IL13&IL4, SAR156597(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA SAR156597
GTTS-WQ5084MR IVTScrip™ mRNA-Anti-CSF2RA, CAM-3001(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CAM-3001
GTTS-WQ15909MR IVTScrip™ mRNA-Anti-IL1B, XOMA 052(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA XOMA 052
GTTS-WQ9808MR IVTScrip™ mRNA-Anti-BTLA, JS004(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA JS004
GTTS-WQ1940MR IVTScrip™ mRNA-Anti-SLITRK6, AGS15C(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA AGS15C
GTTS-WQ12876MR IVTScrip™ mRNA-Anti-TNF, OPRX-106(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA OPRX-106
GTTS-WQ2006MR IVTScrip™ mRNA-Anti-INSR, AGT-181(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AGT-181
GTTS-WQ15683MR IVTScrip™ mRNA-Anti-VEGFA, VEGF Trap(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA VEGF Trap
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW